Cancer is the second-leading cause of American deaths. But last week, scientists at the Cleveland Clinic reported a potentially transformative new treatment, which has already saved three dogs with metastatic tumors from certain death.
The treatment involves the use of a drug that targets the extra vitamin-B12 receptors that allow cancer cells to multiply at such a furious pace. That drug, nitrosylcobalamin (NO-Cbl), attacks the receptors with toxic nitric oxide, selectively killing off the most aggressive tumor tissue. NO-Cbl has been tested only on those three dogs, all of which had advanced adenocarcinomas. But so far, it’s three for three, and the scientists hope to begin Phase 1 human trials within the year.
This post is from Observer Short List—an email of three favorite things from people you want to know. Sign up to receive OSL here.